Milford E L, Kirkman R L, Tilney N L, Strom T B, Carpenter C B
Am J Kidney Dis. 1985 Jun;5(6):313-7. doi: 10.1016/s0272-6386(85)80160-8.
Cyclosporine (CsA) immunosuppressive therapy of renal allograft recipients at Brigham and Women's Hospital yielded a 20% increase in 12- and 24-month allograft survival over azathioprine (Aza) treated controls. A trend towards increased allograft survival with better HLA-A,B, or DR matching in recipients of cadaver allografts treated with CsA was appreciated, but it fell short of statistical significance. Nephrotoxicity is common in CsA-treated patients and is manifested by a largely reversible increase in the serum creatinine. It is possible to convert patients from CsA to Aza without adverse effects on allograft survival or allograft function.
在布莱根妇女医院，接受环孢素（CsA）免疫抑制治疗的肾移植受者，其移植肾12个月和24个月的存活率比接受硫唑嘌呤（Aza）治疗的对照组提高了20%。在用CsA治疗的尸体肾移植受者中，随着HLA - A、B或DR配型更佳，移植肾存活率有增加的趋势，但未达到统计学意义。肾毒性在接受CsA治疗的患者中很常见，表现为血清肌酐大幅可逆性升高。将患者从CsA转换为Aza，对移植肾存活率或移植肾功能没有不良影响。
